Update on China Grand Pharmaceutical and Healthcare Holdings Limited
Sydney, Australia 28 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to provide an update regarding the Company’s negotiations with China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand). As noted in the Company’s Prospectus, Clarity and China Grand agreed…